Skip to content

Study · Randomized controlled trial · 2008

3 results

Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.

Debruyne F, Gres AA, Arustamov DL

European urology1 Apr 2008Cited by 31 (Europe PMC)

PMID18417275 (opens in a new tab)DOI10.1016/j.eururo.2008.03.069 (opens in a new tab)PepBankPUB-18417275
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with symptomatic BPH, peak mean IPSS change was -5.4 to -5.9 with cetrorelix versus -2.8 with placebo.

    In plain wordsIn patients with BPH, symptom scores fell more with cetrorelix (peak change -5.4 to -5.9) than with placebo (-2.8).

    Peptide
    Cetrorelix
    Outcome
    DecreasePeak IPSS improvement
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    5 mg weekly x4, 10 mg every 2 weeks x2, or 10 mg weekly x4 · subcutaneousAs given in this study (human).

    Measurements

    Peak mean IPSS change
    −5.4 to −5.9 IPSS
    cetrorelix groups
    Peak mean IPSS change
    −2.8 IPSS
    placebo

    Source sentences

    Summary
    In all CET groups a rapid improvement in mean IPSS was obtained, with a peak effect of -5.4 to -5.9 (placebo: -2.8).
    3 context sentences
    Summary · context
    After all dosages of CET given, changes from baseline and differences to placebo were statistically significant up to week 20.
    Summary · context
    After a run-in period with 4 weekly injections of placebo, 140 patients with an international prostate symptoms score (IPSS) > or =13 and a peak urinary flow rate (PFR) 5-13ml/s were randomly allocated to 4 treatment groups; patients with residual urine volume of >350ml were excluded.
    Summary · context
    Patients received either CET at dosages of 5mg/wkx4, 10mg/2 wkx2 or 10mg/wkx4 or placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with symptomatic BPH, secondary parameters improved significantly, rapidly, and persistently with all cetrorelix dosages.

    In plain wordsIn patients with BPH, secondary measures improved significantly and persistently with all cetrorelix dosages.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedSecondary parameters
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    5 mg weekly x4, 10 mg every 2 weeks x2, or 10 mg weekly x4 · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Similarly, secondary parameters showed a significant, rapid, and persistent improvement for all CET dosages.
    3 context sentences
    Summary · context
    IPSS, PFR and mean uroflow, residual urinary volume, prostate volume, plasma testosterone, quality of life, and sexual function were evaluated over a total of 20 wk after randomization.
    Summary · context
    After a run-in period with 4 weekly injections of placebo, 140 patients with an international prostate symptoms score (IPSS) > or =13 and a peak urinary flow rate (PFR) 5-13ml/s were randomly allocated to 4 treatment groups; patients with residual urine volume of >350ml were excluded.
    Summary · context
    Patients received either CET at dosages of 5mg/wkx4, 10mg/2 wkx2 or 10mg/wkx4 or placebo.
  3. 03HumanNon-randomized trialSafety outcome

    In patients with symptomatic BPH, all cetrorelix dosage regimens were well tolerated.

    In plain wordsIn patients with BPH, all cetrorelix dosage regimens were well tolerated.

    Peptide
    Cetrorelix
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    5 mg weekly x4, 10 mg every 2 weeks x2, or 10 mg weekly x4 · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    All dosage regimens were well tolerated.
    2 context sentences
    Summary · context
    After a run-in period with 4 weekly injections of placebo, 140 patients with an international prostate symptoms score (IPSS) > or =13 and a peak urinary flow rate (PFR) 5-13ml/s were randomly allocated to 4 treatment groups; patients with residual urine volume of >350ml were excluded.
    Summary · context
    Patients received either CET at dosages of 5mg/wkx4, 10mg/2 wkx2 or 10mg/wkx4 or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.